Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07695896

Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma. Although first-line R-CHOP can cure a proportion of patients, approximately 30%-40% relapse or become refractory (R/R). CD20xCD3 bispecific antibodies, represented by glofitamab, have shown significant efficacy in clinical trials. However, large-scale real-world efficacy and safety data in Chinese clinical practice are still lacking, particularly regarding combination with different regimens and use in the relapsed population.

This is a prospective, multicenter, observational registry study evaluating the efficacy and safety of CD20xCD3 bispecific antibody-containing regimens in patients with relapsed or refractory B-cell non-Hodgkin lymphoma in a real-world setting. Efficacy is assessed using the Lugano 2014 response criteria. The primary endpoint is best objective response rate (ORR).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Disease Attributes Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Study design: Prospective, multicenter, observational (non-interventional) registry study.

Population: Patients aged >=18 years with histologically confirmed B-cell non-Hodgkin lymphoma who are relapsed or refractory after at least one prior line of therapy and who receive a CD20xCD3 bispecific antibody-containing regimen after study initiation.

Efficacy evaluation: Lugano 2014 response criteria.

Primary endpoint: Best objective response rate (ORR).

Secondary endpoints: Complete response rate (CRR), disease control rate (DCR), duration of response (DOR), time to next treatment (TTNT), progression-free survival (PFS), overall survival (OS), and safety.

Exploratory endpoints: Subgroup analyses by combination pattern (e.g., combined with chemotherapy or targeted agents) and special populations; correlation of biomarkers (e.g., peripheral blood lymphocyte subsets, T-lymphocyte mitochondrial immune analysis, cytokines) with efficacy and safety; and patient compliance and quality-of-life analyses based on electronic patient-reported outcomes (ePRO).

Planned enrollment: 200 participants. As a non-interventional study, no formal statistical hypothesis is tested; the sample size is based on the confidence-interval width method (expected ORR P=0.5, half-width d=0.07), yielding approximately 196 participants, rounded to 200.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >= 18 years at the start of treatment
  • Histologically confirmed B-cell non-Hodgkin lymphoma
  • Relapsed or refractory disease after at least one prior line of systemic therapy
  • Planned to receive a CD20xCD3 bispecific antibody-containing regimen after study initiation
  • Signed informed consent for the investigational treatment

Exclusion criteria

  • Currently participating in, or planning to participate in, any interventional clinical trial
  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study

Treatment and study plan

Glofitamab

Biological

Glofitamab, a CD20xCD3 bispecific monoclonal antibody, administered per real-world clinical practice and product labeling. As an observational study, treatment is determined by the treating physician and not by the study protocol; the intervention of interest is recorded to describe the treated population.

Primary outcomes

  1. Best Overall Response Rate (ORR)

    Time frame: From treatment initiation until disease progression or start of new anti-lymphoma therapy, assessed up to approximately 2 years

    ORR is defined as the proportion of participants achieving a best overall response of complete response (CR) or partial response (PR), assessed by the investigator according to the Lugano 2014 response criteria for malignant lymphoma.

Secondary outcomes

  1. Disease Control Rate (DCR)

    Time frame: From treatment initiation until disease progression, assessed up to approximately 2 years

    DCR is defined as the proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) per Lugano 2014 criteria.

  2. Duration of Response (DOR)

    Time frame: From first response until disease progression or death, assessed up to approximately 2 years

    DOR is defined as the time from the first documented CR or PR to the first documented disease progression or death from any cause, whichever occurs first, among responders.

  3. Time to Next Treatment (TTNT)

    Time frame: From treatment initiation until start of next therapy or death, assessed up to approximately 2 years

    TTNT is defined as the time from treatment initiation to the start of the next line of anti-lymphoma therapy or death from any cause, whichever occurs first.

  4. Progression-Free Survival (PFS)

    Time frame: From treatment initiation until disease progression or death, assessed up to approximately 2 years

    PFS is defined as the time from treatment initiation to the first documented disease progression per Lugano 2014 criteria or death from any cause, whichever occurs first.

  5. Overall Survival (OS)

    Time frame: From treatment initiation until death from any cause, assessed up to approximately 2 years

    OS is defined as the time from treatment initiation to death from any cause.

  6. Incidence of Adverse Events (Safety)

    Time frame: From treatment initiation until 90 days after last dose, assessed up to approximately 2 years

    Safety is assessed by the incidence, severity, and type of adverse events (AEs) and serious adverse events (SAEs), including adverse events of special interest such as cytokine release syndrome (CRS), graded per NCI CTCAE and, for CRS, per ASTCT consensus criteria.

  7. Complete Response Rate (CRR)

    Time frame: From treatment initiation until disease progression or start of new therapy, assessed up to approximately 2 years

    CRR is defined as the proportion of participants achieving a best overall response of complete response (CR) per Lugano 2014 criteria.

Study contacts

Contact information is provided by the study sponsor or research team.

Yanyan Liu

CONTACT

[email protected]

+86 13838176375

Sponsors and collaborators

Lead sponsor

Yanyan Liu

Other Gov

Registry information

Official study title

A Real-World Study on the Efficacy and Safety of Bispecific Antibody in the Treatment of Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jul 10, 2026
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.